Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Tumor-Agnostic 3Plasma cell 2Other hematologic neoplasm 2Myeloid 2Lymphoid 2CNS 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1

Interventions

Cytarabine 905Cyclophosphamide 899fludarabine 525venetoclax 489fludarabine phosphate 468Azacitidine 460Rituximab 431Methotrexate 419Etoposide 320Filgrastim 299Busulfan 296Dexamethasone 286Vincristine 285Daunorubicin 283Peripheral Blood Stem Cell Transplantation 258Whole-Body Irradiation 243Mycophenolic Acid 232Decitabine 230Granulocyte Colony-Stimulating Factor 227Tacrolimus 220Imatinib Mesylate 211Idarubicin 205Melphalan 202Cyclosporine 182Doxorubicin 177Radiotherapy 169Prednisone 164Dasatinib 163Mitoxantrone 161Lenalidomide 160

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Capsules × Other hematologic neoplasm × Clear all
NCT02629692 2026-05-13

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Sun Pharma Advanced Research Company Limited

Phase 1/2 Terminated
124 enrolled 51 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04942730 2024-05-07

FluBuBe

St. Petersburg State Pavlov Medical University

Phase 2 Completed
50 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡